Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 884.00Kに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 884.00Kです。
適正水準
同社の最新のPEは-2.60で、過去3年間の水準と比較して適正圏にあります。
機関投資家の買い増し
最新の機関投資家の保有株数は61.79M株で、前四半期比で3.74%増加しています。
ETHSXが保有
スター投資家ETHSXは本銘柄を24.10K株保有しています。
市場活動が活発
同社への投資家の関心が高まっており、20日間の売買回転率は0.47です。